Ahmet Tezel

Loading
Ahmet Tezel

Ahmet Tezel

Vice President, R&D, Ethicon
Ahmet Tezel is Vice President, R&D for Ethicon, part of the Johnson & Johnson Medical Devices Companies. In this role, he is responsible for all aspects of research and development efforts for the Ethicon business, driving the innovation strategy and delivering new and innovative products that benefit surgeons and improve patient care. Ahmet is a member of the Medical Devices R&D and Ethicon Leadership Teams. Ahmet joined Johnson & Johnson in 2020, with broad experience in the medical device industry including a strong history of delivering new products to the market. Prior to joining the company, he held various executive positions in research, development and tech transfer within Alcon and Allergan. Most recently, he was the Surgical Franchise Head of Research & Development for Alcon in Fort Worth, TX where he led all R&D activities for a broad portfolio of products including femto/excimer lasers, cataract, vitreoretinal and diagnostic capital equipment, digital health, consumables/disposables, and Class III implantables. Earlier in his career, Ahmet held increasing leadership roles at Allergan’s Medical Device R&D in Santa Barbara, CA working across a wide range of medical specialties. Ahmet holds a Ph.D. in Chemical Engineering from University of California, Santa Barbara in Transdermal drug delivery and vaccination, as well as a B.Sc., and M.Sc., Chemical Engineering from Bogazici University in Istanbul, Turkey. He has been published in 16 peer reviewed publications in the areas of transdermal drug delivery, transcutaneous vaccination, and medical aesthetics. Ahmet holds 18 patents in the technology areas of biomedical polymers and electromechanical medical devices. He is also an Industry Board Member for University of California Santa Barbara Materials Research Lab.
Sessions
  • “Future Surgery 2021 will be the first of its kind in the UK, drawing on the work our Commission on the Future of Surgery has done to predict the transformation in the medical care for millions of patients.”
    Andrew Reed, Chief Executive of the Royal College of Surgeons of England
  • “Driven by changes in digital technologies and our fast-evolving understanding of genomics, innovations are expected to affect how we undertake surgery, and how we train surgeons in future.”
    Andrew Reed, Chief Executive of the Royal College of Surgeons of England
  • "Alongside the conference organisers, CloserStill, we aim to deliver a high-quality event that will provide both professional development and discussion space for surgeons and their teams."
    Andrew Reed, Chief Executive of the Royal College of Surgeons of England
  • "We look forward to welcoming colleagues to what promises to be a very high-quality programme and an exciting two days of thought-provoking training and engagement with medical suppliers."
    Andrew Reed, Chief Executive of the Royal College of Surgeons of England

EVENT PARTNER


 

PLATINUM SPONSOR

Edinurgh

PLATINUM SPONSOR

CMR

PLATINUM SPONSOR

quilter

GOLD SPONSOR


 

GOLD SPONSOR


 

GOLD SPONSOR

Sony

Sustainability Sponsor

SPONSOR

AneticAid

SPONSOR


 

SPONSOR


 

SPONSOR

Creed Medical

SPONSOR

Corza Medical

SPONSOR


 

SPONSOR

Epiqar

SPONSOR

Fundamental Surgery

SPONSOR


 

SPONSOR

Intuitive

SPONSOR


 

SPONSOR


 

SPONSOR


 

SPONSOR


 

SPONSOR


 

SPONSOR

  • Open Medical

 

SPONSOR

  • 365 Healthcare

 

Event Supporter


 

Event Supporter


 

Event Supporter


 

Event Supporter

British Orthopaedic Association

Event Supporter


 

Event Supporter


 

Event Supporter


 

Event Supporter


 

Event Supporter

SSSIM

MEDIA PARTNER

CSJ

MEDIA PARTNER

Operating Theatre Journal